CME Presentations




  • Naval Daver, MD

    Naval Daver, MD

    Naval Daver, MD

    Associate Professor

    Naval Daver, MD, is an Associate Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center. He is a clinical investigator with a focus on molecular and immune therapies in AML and myeloid disease and is principal investigator on over 25 ongoing institutional, national, and international clinical trials in these diseases. Dr. Daver is interested in developing monoclonal and bispecific antibodies and T-cell based approaches as well as combinations of targeted and apoptotic therapies in AML. He’s published over 400 peer-reviewed manuscripts and is on the editorial board of numerous hematology journals and societies. In addition, Dr. Daver serves as Chair on numerous national and international meetings and educational platforms.
  • David Sallman, MD

    David Sallman, MD

    David Sallman, MD

    Assistant Member, Department of Malignant Hematology (DMH)

    David Sallman, MD, is an Assistant Member in the Department of Malignant Hematology (DMH) at Moffitt Cancer Center, Assistant Professor in the Department of Oncologic Sciences at the University of South Florida, and the Myeloid Section Head of the DMH. His clinical interests are myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and myeloproliferative neoplasms. His research interests focus on the development of novel therapeutic strategies for patients with MDS and AML. Specifically, he studies the genetic drivers of myeloid diseases to improve prognostication for patients and to allow for more personalized treatment. He is the PI for multiple ongoing studies focused on higher-risk MDS; has authored numerous articles, books, etc.; and serves as reviewer for multiple journals.

CME Information

PACE Logo PQH Logo
Strategies to Address Real-World Challenges in High-Risk Myelodysplastic Syndrome
Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC.


This program has been supported by an independent educational grant from Gilead Sciences, Inc.


This activity was released on April 6, 2023 and is valid until April 6, 2024. Requests for credit must be made no later than April 6, 2024.


The educational design of this activity addresses the needs of hematologic oncologists, hematologists, medical oncologists, oncology advanced practice providers (NPs and PAs), oncology nurses, pharmacists, and other clinicians involved in the management of patients with myelodysplastic syndrome (MDS).


While approved chemotherapies and allogeneic stem-cell transplant have shown some success in the treatment of myelodysplastic syndrome (MDS), patients can still relapse or become refractory to treatment. Based on their risk stratification, patients with MDS need to receive the most suitable and effective therapy upfront. Clinical trials on immunotherapies for MDS are ongoing and agents with novel mechanisms are showing promising results.

Join a panel of expert hematologists and oncologists to review the team- and system-based gaps that prevent timely integration of new therapies for MDS. Panelists will share strategies to overcome barriers to the use of new advances in care and to create personalized treatment plans for patients with high-risk MDS based on their needs and preferences. Clinicians will learn how to select the right patients for novel therapies, whether through participation in clinical trials or in preparation of anticipated approvals.


After completing this activity, the participant should be better able to:
  • Discuss the rationale for and mechanisms of action of novel immunotherapies for high-risk MDS
  • Evaluate efficacy and safety profiles of emerging immunotherapies for high-risk MDS
  • Outline strategies to individualize treatment plans for patients with high-risk MDS and align care with clinical guidelines


In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 60 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Name of Faculty or Presenter Reported Financial Relationship
Naval Daver, MD
Associate Professor
Director, Leukemia Research Alliance Program
Department of Leukemia
MD Anderson Cancer Center
Consultant, Advisor, Speaker: AbbVie; Agios; Amgen; Arog; Astellas; Bristol-Meyers Squibb; Celgene; Daichii-Sankyo; Gilead; ImmunoGen; Jazz; Novartis; Pfizer; Servier; Servier; Shattuck Labs; Syndax; and Trillium.

Researcher: AbbVie; Amgen; Astellas; Bristol-Meyers Squibb; Daichii-Sankyo; FATE Therapeutics; Genentech; Gilead; Glycomimetics; Hanmi Pharmaceutical; ImmunoGen; Novimmune; Pfizer; Servier; Trillium; and Trovagene.
David Sallman, MD
Assistant Member
Myeloid Malignancies Section Head, Malignant Hematology
Moffitt Cancer Center
Consultant, Advisor, Speaker: AbbVie; Affimed Gmbh; Avencell; Bluebird Bio; Bristol Myers Squibb; Gilead; Incyte; Intellia; Intellisphere, LLC; Jasper Therapeutics; Kite; Molecular Partners AG; Novartis; PGEN Therapeutics, Inc.; Servier; Shattack Labs; Syndax; Takeda; and Zentails.

Researcher: Aprea and Jazz

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support:

For additional information about the accreditation of this activity, please visit

Technical Support:

For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at